NOS2 and glioma: Indeed, when iNOS was targeted using either small molecular inhibitor or shRNA, there was a significant loss in tumorigenesis in both human and murine glioma cells [55], demonstrating that GSCs-derived iNOS may be a potential therapeutic target.